Aug. 18 at 4:38 PM
$ENSC Following the end of the second quarter, Ensysce completed the acquisition of Cy Biopharma and the associated financing, marking an important step in the continued evolution of our pain-focused clinical portfolio.
The transaction added CY200, a clinical-stage psychedelic agent being developed for Complex Regional Pain Syndrome Type 1 and designated by the FDA as an Orphan Drug, while providing approximately
$31 million in net proceeds to support its development.
With current resources expected to support operations into late 2027, Ensysce enters this next stage with a broader clinical pipeline and additional capital to add to its non-dilutive federal government funding for PF614-MPAR program.
We remain focused on advancing these programs to provide a meaningful solution to those in severe pain.
